<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984395</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5459</org_study_id>
    <nct_id>NCT04984395</nct_id>
  </id_info>
  <brief_title>Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer</brief_title>
  <acronym>IDT</acronym>
  <official_title>Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer Through Better Imaging With Whole-Body Magnetic Resonance Imaging With Diffusion Weighted Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to provide clinical evidence to determine if Whole Body Magnetic&#xD;
      Resonance Imaging (WBMRI) with a novel technique called diffusion-weighted imaging (DWI) can&#xD;
      improve current treatment for APC patients, allowing for early identification of disease&#xD;
      progression or treatment response, hence facilitating clinical decision-making and leading to&#xD;
      improvement in patient care. The IDT study includes two retrospective analyses and a single&#xD;
      centre prospective observational study for APC patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic Advanced Prostate Cancer occurs when cancer spreads from the prostate to other&#xD;
      parts of the body (bones, lymph nodes or other organs), with bones being the commonest site&#xD;
      of spread in prostate cancer. These cancer growths are called metastases. APC metastases are&#xD;
      diverse (heterogeneous) in their growth pattern, such that not all metastases will respond to&#xD;
      the same treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective analysis: WBMRI parameters</measure>
    <time_frame>Month 1-26</time_frame>
    <description>Prognostic association of derived pre-treatment WBMRI parameters, total disease volume (tDV) and apparent diffusion coefficient (ADC) for prediction of overall survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrospective analysis: Diagnostic performance of MET-RADS-P</measure>
    <time_frame>Month 1-26</time_frame>
    <description>Accuracy of MET-RADS-P to assess response to systemic treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Single centre prospective observational imaging study</measure>
    <time_frame>Month 6-38</time_frame>
    <description>Pairwise correlations of percentage of ADC change with:&#xD;
Tumour regression grading according to the international system of Salzer-Kuntschnik&#xD;
Changes in biopsy tumour content and tumour/necrosis ratio&#xD;
Fat fraction percentage with bone marrow adipose tissue/fibrosis reported by histopathology analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retrospective analysis: WBMRI parameters</measure>
    <time_frame>Month 1-26</time_frame>
    <description>Prognostic association of baseline tDV and ADC for prediction of radiographic Progression Free Survival (rPFS) using Prostate Cancer Working Group 3 criteria (PCWG3) and Skeletal Related Events (SREs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective analysis: Diagnostic performance of MET-RADS-P</measure>
    <time_frame>Month 1-26</time_frame>
    <description>Inter-observer agreement - determine prognostic association of MET-RADS-P response for prediction of overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single centre prospective observational imaging study</measure>
    <time_frame>Month 6-38</time_frame>
    <description>Fraction of bone biopsies with sufficient tumour yield for genomic sequencing.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Prostate Carcinoma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Post-treatment CT-guided bone marrow biopsy</intervention_name>
    <description>At post-treatment, 12 +/- 3 weeks after initiating treatment, patients will undergo a CT guided bone marrow biopsy of the same lesion as baseline.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bone marrow biopsy.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic, advanced prostate cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Retrospective study A Baseline WBMRI scans in metastatic APC patients acquired up to 8&#xD;
        weeks prior to the initiation of a new line of therapy.&#xD;
&#xD;
        Retrospective study B Paired WBMRI scans in metastatic APC patients at baseline within 8&#xD;
        weeks prior to treatment and at 12 ± 3 weeks after systemic treatment&#xD;
&#xD;
        Prospective study C Written informed consent. Age ≥18 years. Advanced prostate cancer&#xD;
        patients with indication for systemic anti-cancer therapy to be enrolled in a clinical&#xD;
        study.&#xD;
&#xD;
        Participants must have a baseline WBMRI and CT-guided bone marrow biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Prospective Study C Patient is claustrophobic. Contraindications to MRI examination (e.g.,&#xD;
        cardiac pacemakers, cochlear implants).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male with prostate cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Tunariu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Marsden NHS FT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Ribeiro</last_name>
    <phone>02089156499</phone>
    <email>ana.ribeiro@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiaan Jacobs</last_name>
    <phone>02089156499</phone>
    <email>tiaan.jacobs@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Ribeiro</last_name>
      <phone>02089156499</phone>
      <email>ana.ribeiro@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Tiaan Jacobs</last_name>
      <email>tiaan.jacobs@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dow-Mu Koh, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Tunariu, Consultant</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann DeBono, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The main study results will be published in a peer-reviewed journal, on behalf of all collaborators. The manuscript will be prepared by a writing group, consisting of members of the Study Management Group.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Fully anonymised trial data will be made available.</ipd_time_frame>
    <ipd_access_criteria>Data Sharing / Transfer Agreements to be in place.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

